Palvella Therapeutics (PVLA) Expected to Release Earnings on Thursday

Palvella Therapeutics (NASDAQ:PVLA) will likely be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Palvella Therapeutics to announce earnings of ($1.72) per share and revenue of $0.02 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Palvella Therapeutics (NASDAQ:PVLA) last announced its earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). On average, analysts expect Palvella Therapeutics to post ($6.39) EPS for the current fiscal year and ($8.61) EPS for the next fiscal year.

Palvella Therapeutics Stock Up 4.5%

Shares of NASDAQ PVLA opened at $152.93 on Wednesday. Palvella Therapeutics has a twelve month low of $71.55 and a twelve month high of $161.38. The stock has a fifty day simple moving average of $141.70 and a 200-day simple moving average of $127.15.

Insider Activity

In related news, COO Kathleen Goin sold 4,313 shares of the company’s stock in a transaction that occurred on Wednesday, October 21st. The shares were sold at an average price of $124.58, for a total transaction of $537,313.54. Following the sale, the chief operating officer directly owned 2,165 shares in the company, valued at approximately $269,715.70. This represents a 66.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher P. Kiritsy sold 313 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $157.00, for a total transaction of $49,141.00. Following the sale, the director owned 250 shares in the company, valued at $39,250. The trade was a 55.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 61,056 shares of company stock worth $8,756,946. 17.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

PVLA has been the subject of several research reports. Raymond James Financial set a $226.00 target price on Palvella Therapeutics in a research report on Friday, October 16th. Chardan Capital reiterated a “buy” rating and set a $240.00 target price on shares of Palvella Therapeutics in a report on Wednesday, October 28th. William Blair assumed coverage on shares of Palvella Therapeutics in a research report on Friday, October 16th. They issued an “outperform” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Friday, September 25th. Finally, HC Wainwright restated a “buy” rating on shares of Palvella Therapeutics in a research note on Tuesday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $209.79.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing treatments for patients with serious rare diseases, including conditions that may have limited or no approved therapeutic options.

The company’s development programs are based on its QTORIN 3.0 technology platform, which is designed to deliver medicines locally through topical formulations. Palvella has applied the platform to investigational therapies for rare genetic skin disorders and other localized diseases, with the goal of improving treatment effectiveness while limiting systemic exposure.

Palvella is headquartered in Wayne, Pennsylvania, and conducts research and development activities aimed at serving rare-disease patients in the United States and other potential international markets.